Which has preferable valuation & earnings, SIBN or PLSE?

SiBone has higher revenue and earnings than Pulse Biosciences. SiBone is trading at a lower price-to-earnings ratio than Pulse Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SiBone $200.93M 4.18 -$18.90M -$0.34 N/A Pulse Biosciences $350K 8,807.47 -$72.78M -$1.18 N/A

Is SIBN or PLSE more profitable?

SiBone has a net margin of -6.85% compared to Pulse Biosciences' net margin of -6,755.78%. SiBone's return on equity of -8.23% beat Pulse Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets SiBone -6.85% -8.23% -6.07% Pulse Biosciences -6,755.78% -94.42% -79.96%

Does the media favor SIBN or PLSE?

In the previous week, Pulse Biosciences had 6 more articles in the media than SiBone. MarketBeat recorded 8 mentions for Pulse Biosciences and 2 mentions for SiBone. SiBone's average media sentiment score of 1.22 beat Pulse Biosciences' score of 0.97 indicating that SiBone is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SiBone 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pulse Biosciences 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, SIBN or TMDX?

TransMedics Group has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SiBone $200.93M 4.18 -$18.90M -$0.34 N/A TransMedics Group $605.49M 5.06 $190.29M $3.89 22.77

Does the media favor SIBN or TMDX?

In the previous week, TransMedics Group had 6 more articles in the media than SiBone. MarketBeat recorded 8 mentions for TransMedics Group and 2 mentions for SiBone. SiBone's average media sentiment score of 1.22 beat TransMedics Group's score of 0.71 indicating that SiBone is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SiBone 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TransMedics Group 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, SIBN or AXGN?

AxoGen has higher revenue and earnings than SiBone. AxoGen is trading at a lower price-to-earnings ratio than SiBone, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SiBone $200.93M 4.18 -$18.90M -$0.34 N/A AxoGen $225.21M 11.63 -$15.70M -$0.68 N/A

Is SIBN or AXGN more profitable?

SiBone has a net margin of -6.85% compared to AxoGen's net margin of -13.36%. SiBone's return on equity of -8.23% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets SiBone -6.85% -8.23% -6.07% AxoGen -13.36% -8.90% -6.47%

Does the media favor SIBN or AXGN?

In the previous week, AxoGen had 8 more articles in the media than SiBone. MarketBeat recorded 10 mentions for AxoGen and 2 mentions for SiBone. SiBone's average media sentiment score of 1.22 beat AxoGen's score of 0.61 indicating that SiBone is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SiBone 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AxoGen 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, SIBN or BFLY?

SiBone has higher revenue and earnings than Butterfly Network. SiBone is trading at a lower price-to-earnings ratio than Butterfly Network, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SiBone $200.93M 4.18 -$18.90M -$0.34 N/A Butterfly Network $97.61M 24.16 -$77.06M -$0.29 N/A

Does the media refer more to SIBN or BFLY?

In the previous week, Butterfly Network had 11 more articles in the media than SiBone. MarketBeat recorded 13 mentions for Butterfly Network and 2 mentions for SiBone. SiBone's average media sentiment score of 1.22 beat Butterfly Network's score of 0.55 indicating that SiBone is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SiBone 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Butterfly Network 6 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ESTA or SIBN more profitable?

SiBone has a net margin of -6.85% compared to Establishment Labs' net margin of -15.82%. SiBone's return on equity of -8.23% beat Establishment Labs' return on equity. Company Net Margins Return on Equity Return on Assets Establishment Labs -15.82% -196.69% -10.73% SiBone -6.85% -8.23% -6.07%

Does the media prefer ESTA or SIBN?

In the previous week, Establishment Labs had 4 more articles in the media than SiBone. MarketBeat recorded 6 mentions for Establishment Labs and 2 mentions for SiBone. SiBone's average media sentiment score of 1.22 beat Establishment Labs' score of 0.95 indicating that SiBone is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Establishment Labs 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SiBone 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

SiBone (SIBN) Competitors

$18.93 -0.02 (-0.11%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$18.92 -0.01 (-0.05%)

As of 08/14/2026 04:10 PM Eastern

Compare

SIBN vs. PLSE, TMDX, AXGN, BFLY, and ESTA

Should you buy SiBone stock or one of its competitors? SiBone's main competitors and comparable companies include Pulse Biosciences (PLSE), TransMedics Group (TMDX), AxoGen (AXGN), Butterfly Network (BFLY), and Establishment Labs (ESTA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does SiBone compare to Pulse Biosciences?

SiBone (NASDAQ:SIBN) and Pulse Biosciences (NASDAQ:PLSE) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

SiBone has a net margin of -6.85% compared to Pulse Biosciences' net margin of -6,755.78%. SiBone's return on equity of -8.23% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-6.85%	-8.23%	-6.07%
Pulse Biosciences	-6,755.78%	-94.42%	-79.96%

SiBone has higher revenue and earnings than Pulse Biosciences. SiBone is trading at a lower price-to-earnings ratio than Pulse Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$200.93M	4.18	-$18.90M	-$0.34	N/A
Pulse Biosciences	$350K	8,807.47	-$72.78M	-$1.18	N/A

SiBone has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market. Comparatively, Pulse Biosciences has a beta of 1.61, suggesting that its share price is 61% more volatile than the broader market.

SiBone currently has a consensus price target of $24.17, suggesting a potential upside of 27.66%. Pulse Biosciences has a consensus price target of $41.00, suggesting a potential downside of 7.95%. Given SiBone's stronger consensus rating and higher probable upside, equities research analysts plainly believe SiBone is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

98.1% of SiBone shares are held by institutional investors. Comparatively, 77.0% of Pulse Biosciences shares are held by institutional investors. 4.0% of SiBone shares are held by insiders. Comparatively, 74.0% of Pulse Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Pulse Biosciences had 6 more articles in the media than SiBone. MarketBeat recorded 8 mentions for Pulse Biosciences and 2 mentions for SiBone. SiBone's average media sentiment score of 1.22 beat Pulse Biosciences' score of 0.97 indicating that SiBone is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SiBone	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pulse Biosciences	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

SiBone beats Pulse Biosciences on 11 of the 16 factors compared between the two stocks.

How does SiBone compare to TransMedics Group?

SiBone (NASDAQ:SIBN) and TransMedics Group (NASDAQ:TMDX) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, media sentiment, valuation and risk.

98.1% of SiBone shares are held by institutional investors. Comparatively, 99.7% of TransMedics Group shares are held by institutional investors. 4.0% of SiBone shares are held by insiders. Comparatively, 6.9% of TransMedics Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

TransMedics Group has a net margin of 22.69% compared to SiBone's net margin of -6.85%. TransMedics Group's return on equity of 15.88% beat SiBone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-6.85%	-8.23%	-6.07%
TransMedics Group	22.69%	15.88%	5.95%

SiBone presently has a consensus target price of $24.17, suggesting a potential upside of 27.66%. TransMedics Group has a consensus target price of $124.18, suggesting a potential upside of 40.19%. Given TransMedics Group's higher possible upside, analysts clearly believe TransMedics Group is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38

TransMedics Group has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$200.93M	4.18	-$18.90M	-$0.34	N/A
TransMedics Group	$605.49M	5.06	$190.29M	$3.89	22.77

SiBone has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market. Comparatively, TransMedics Group has a beta of 1.9, suggesting that its share price is 90% more volatile than the broader market.

In the previous week, TransMedics Group had 6 more articles in the media than SiBone. MarketBeat recorded 8 mentions for TransMedics Group and 2 mentions for SiBone. SiBone's average media sentiment score of 1.22 beat TransMedics Group's score of 0.71 indicating that SiBone is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SiBone	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TransMedics Group	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

TransMedics Group beats SiBone on 13 of the 15 factors compared between the two stocks.

How does SiBone compare to AxoGen?

SiBone (NASDAQ:SIBN) and AxoGen (NASDAQ:AXGN) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and risk.

SiBone has a net margin of -6.85% compared to AxoGen's net margin of -13.36%. SiBone's return on equity of -8.23% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-6.85%	-8.23%	-6.07%
AxoGen	-13.36%	-8.90%	-6.47%

SiBone currently has a consensus price target of $24.17, suggesting a potential upside of 27.66%. AxoGen has a consensus price target of $51.00, suggesting a potential upside of 4.66%. Given SiBone's higher possible upside, analysts plainly believe SiBone is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

98.1% of SiBone shares are owned by institutional investors. Comparatively, 80.3% of AxoGen shares are owned by institutional investors. 4.0% of SiBone shares are owned by company insiders. Comparatively, 2.4% of AxoGen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

AxoGen has higher revenue and earnings than SiBone. AxoGen is trading at a lower price-to-earnings ratio than SiBone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$200.93M	4.18	-$18.90M	-$0.34	N/A
AxoGen	$225.21M	11.63	-$15.70M	-$0.68	N/A

In the previous week, AxoGen had 8 more articles in the media than SiBone. MarketBeat recorded 10 mentions for AxoGen and 2 mentions for SiBone. SiBone's average media sentiment score of 1.22 beat AxoGen's score of 0.61 indicating that SiBone is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SiBone	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AxoGen	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SiBone has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market. Comparatively, AxoGen has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market.

Summary

SiBone beats AxoGen on 9 of the 16 factors compared between the two stocks.

How does SiBone compare to Butterfly Network?

SiBone (NASDAQ:SIBN) and Butterfly Network (NYSE:BFLY) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment.

SiBone has higher revenue and earnings than Butterfly Network. SiBone is trading at a lower price-to-earnings ratio than Butterfly Network, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$200.93M	4.18	-$18.90M	-$0.34	N/A
Butterfly Network	$97.61M	24.16	-$77.06M	-$0.29	N/A

98.1% of SiBone shares are owned by institutional investors. Comparatively, 37.9% of Butterfly Network shares are owned by institutional investors. 4.0% of SiBone shares are owned by insiders. Comparatively, 22.0% of Butterfly Network shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Butterfly Network had 11 more articles in the media than SiBone. MarketBeat recorded 13 mentions for Butterfly Network and 2 mentions for SiBone. SiBone's average media sentiment score of 1.22 beat Butterfly Network's score of 0.55 indicating that SiBone is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SiBone	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Butterfly Network	6 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SiBone has a net margin of -6.85% compared to Butterfly Network's net margin of -66.74%. SiBone's return on equity of -8.23% beat Butterfly Network's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-6.85%	-8.23%	-6.07%
Butterfly Network	-66.74%	-33.99%	-22.96%

SiBone presently has a consensus target price of $24.17, suggesting a potential upside of 27.66%. Butterfly Network has a consensus target price of $5.56, suggesting a potential downside of 37.19%. Given SiBone's stronger consensus rating and higher probable upside, analysts plainly believe SiBone is more favorable than Butterfly Network.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Butterfly Network	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

SiBone has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market. Comparatively, Butterfly Network has a beta of 2.09, meaning that its stock price is 109% more volatile than the broader market.

Summary

SiBone beats Butterfly Network on 10 of the 16 factors compared between the two stocks.

How does SiBone compare to Establishment Labs?

Establishment Labs (NASDAQ:ESTA) and SiBone (NASDAQ:SIBN) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.

SiBone has lower revenue, but higher earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than SiBone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Establishment Labs	$211.08M	11.22	-$51.06M	-$1.31	N/A
SiBone	$200.93M	4.18	-$18.90M	-$0.34	N/A

SiBone has a net margin of -6.85% compared to Establishment Labs' net margin of -15.82%. SiBone's return on equity of -8.23% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Establishment Labs	-15.82%	-196.69%	-10.73%
SiBone	-6.85%	-8.23%	-6.07%

72.9% of Establishment Labs shares are owned by institutional investors. Comparatively, 98.1% of SiBone shares are owned by institutional investors. 10.0% of Establishment Labs shares are owned by insiders. Comparatively, 4.0% of SiBone shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Establishment Labs has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market. Comparatively, SiBone has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market.

In the previous week, Establishment Labs had 4 more articles in the media than SiBone. MarketBeat recorded 6 mentions for Establishment Labs and 2 mentions for SiBone. SiBone's average media sentiment score of 1.22 beat Establishment Labs' score of 0.95 indicating that SiBone is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Establishment Labs	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SiBone	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Establishment Labs presently has a consensus price target of $100.25, suggesting a potential upside of 26.15%. SiBone has a consensus price target of $24.17, suggesting a potential upside of 27.66%. Given SiBone's higher possible upside, analysts plainly believe SiBone is more favorable than Establishment Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Establishment Labs	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

SiBone beats Establishment Labs on 9 of the 16 factors compared between the two stocks.

Get SiBone News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SIBN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SIBN vs. The Competition

Export

Metric	SiBone	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$839.53M	$5.97B	$7.03B	$13.07B
Dividend Yield	N/A	1.75%	2.57%	10.64%
P/E Ratio	-55.68	26.59	271.54	25.40
Price / Sales	4.18	69.41	673.88	125.76
Price / Cash	N/A	33.36	75.70	53.27
Price / Book	4.61	6.17	12.92	6.21
Net Income	-$18.90M	$149.27M	$3.45B	$347.71M
7 Day Performance	1.72%	2.04%	1.17%	1.08%
1 Month Performance	6.83%	4.02%	2.18%	1.87%
1 Year Performance	22.45%	9.03%	62.39%	20.79%

SiBone Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SIBN SiBone	3.1471 of 5 stars	$18.93 -0.1%	$24.17 +27.7%	+22.4%	$839.53M	$200.93M	N/A	350
PLSE Pulse Biosciences	1.2042 of 5 stars	$44.61 +7.5%	$41.00 -8.1%	+175.6%	$3.09B	$1.19M	N/A	140	News Coverage
TMDX TransMedics Group	4.4979 of 5 stars	$87.43 -1.1%	$124.18 +42.0%	-30.6%	$3.01B	$605.49M	22.40	210
AXGN AxoGen	2.5052 of 5 stars	$48.67 +0.9%	$51.00 +4.8%	+226.4%	$2.62B	$251.17M	N/A	450	Insider Trade
BFLY Butterfly Network	0.9224 of 5 stars	$9.47 -2.4%	$5.56 -41.2%	+519.3%	$2.52B	$97.61M	N/A	460	Insider Trade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SIBN) was last updated on 8/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SiBone (SIBN) Competitors

SIBN vs. PLSE, TMDX, AXGN, BFLY, and ESTA

How does SiBone compare to Pulse Biosciences?

Summary

How does SiBone compare to TransMedics Group?

Summary

How does SiBone compare to AxoGen?

Summary

How does SiBone compare to Butterfly Network?

Summary

How does SiBone compare to Establishment Labs?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SIBN vs. The Competition

SiBone Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SiBone (SIBN) Competitors

SIBN vs. PLSE, TMDX, AXGN, BFLY, and ESTA

How does SiBone compare to Pulse Biosciences?

Is SIBN or PLSE more profitable?

Which has preferable valuation & earnings, SIBN or PLSE?

Which has more risk & volatility, SIBN or PLSE?

Do analysts prefer SIBN or PLSE?

Do institutionals & insiders hold more shares of SIBN or PLSE?

Does the media favor SIBN or PLSE?

Summary

How does SiBone compare to TransMedics Group?

Do insiders & institutionals hold more shares of SIBN or TMDX?

Is SIBN or TMDX more profitable?

Do analysts prefer SIBN or TMDX?

Which has stronger earnings and valuation, SIBN or TMDX?

Which has more volatility & risk, SIBN or TMDX?

Does the media favor SIBN or TMDX?

Summary

How does SiBone compare to AxoGen?

Is SIBN or AXGN more profitable?

Do analysts prefer SIBN or AXGN?

Do insiders and institutionals hold more shares of SIBN or AXGN?

Which has higher valuation and earnings, SIBN or AXGN?

Does the media favor SIBN or AXGN?

Which has more volatility and risk, SIBN or AXGN?

Summary

How does SiBone compare to Butterfly Network?

Which has preferable valuation & earnings, SIBN or BFLY?

Do institutionals & insiders hold more shares of SIBN or BFLY?

Does the media refer more to SIBN or BFLY?

Is SIBN or BFLY more profitable?

Do analysts prefer SIBN or BFLY?

Which has more risk & volatility, SIBN or BFLY?

Summary

How does SiBone compare to Establishment Labs?

Which has better earnings & valuation, ESTA or SIBN?

Is ESTA or SIBN more profitable?

Do institutionals and insiders hold more shares of ESTA or SIBN?

Which has more volatility and risk, ESTA or SIBN?

Does the media prefer ESTA or SIBN?

Do analysts recommend ESTA or SIBN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SIBN vs. The Competition

SiBone Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools